https://www.indianpharmapost.com/gland-pharmas-q2-fy23-revenue-stood-at-rs-10444-cr-132152022-10-27T00:00:00+05:30always0.9https://www.indianpharmapost.com/dabur-india-posts-consolidated-q2-fy2023-pat-at-rs-49006-cr-132162022-10-27T00:00:00+05:30always0.9https://www.indianpharmapost.com/zydus-gets-usfdas-approval-for-ketorolac-tromethamine-tablets-132172022-10-27T00:00:00+05:30always0.9https://www.indianpharmapost.com/usfda-issues-a-crl-for-the-biologics-license-application-for-insulin-aspart-132182022-10-27T00:00:00+05:30always0.9https://www.indianpharmapost.com/camizestrant-significantly-improved-pfs-vs-faslodex-in-serena-2-phase-ii-trial-132192022-10-27T00:00:00+05:30always0.9https://www.indianpharmapost.com/robert-m-davis-is-the-new-chairman-of-merck-132202022-10-27T00:00:00+05:30always0.9https://www.indianpharmapost.com/eres-iv-acquires-a-majority-stake-in-oncodesign-services-132212022-10-27T00:00:00+05:30always0.9https://www.indianpharmapost.com/laurus-labs-planning-rs-2000-cr-capex-132222022-10-27T00:00:00+05:30always0.9